Drug Eluting Balloon Market Size
| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| CAGR | 18.00% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players*Disclaimer: Major Players sorted in no particular order |
Drug Eluting Balloon Market Analysis
The Drug Eluting Balloon Market is expected to register a CAGR of 18% during the forecast period.
COVID-19 had a significant impact on the growth of the market. The COVID-19 pandemic has negatively affected surgical procedures due to the high rate of infection and lockdown restrictions. A delay in diagnosis and treatments was also observed in patients with cardiovascular diseases as a result of a reduction of footfall in hospitals and diagnostic centers, which impacted the market studied as well. Such delay in diagnosis and treatment led to a slight decrease in the demand for drug-eluting balloons, thereby affecting the growth of the market. For instance, according to a research study published in NCBI in March 2022, there was a 52.7% reduction in the volume of adult cardiac surgeries and a 65.5% reduction in elective cases, which indicated the negative impact of COVID-19 on cardiac surgical procedures. However, another NCBI research study published in April 2021 stated that COVID-19 could increase the development of atherosclerosis due to ACE2, which is also a receptor for the SARS-CoV-2 virus. Thus, the long-term effect of COVID-19 on the human body may increase the prevalence of atherosclerosis and other cardiac diseases, which is expected to increase the demand for drug-eluting balloons, thereby by contributing to the growth of the market.
The increasing incidence of coronary and peripheral artery diseases around the world is expected to boost the market's growth. In addition, increasing research and development supported by government and private institutions and continuous initiatives about awareness regarding heart diseases are fuelling the market growth.
According to the Australian Institute of Health and Welfare, in May 2022, out of 11.8 million admissions, 7.0% of hospitalizations involved a stay in the intensive care unit, and 3.8% of hospitalizations involved cardiovascular diseases. According to the American Heart Association 2021 report, peripheral artery disease (PAD) affects more than 200 million people worldwide and is associated with high mortality and morbidity. Moreover, the increasing geriatric population, which is prone to cardiovascular diseases, and growing healthcare spending are projected to bolster market growth. For instance, according to the research study published in December 2021, by Elsevier, for older people aged 45 and above, the overall self-reported prevalence of diagnosed cardiovascular diseases (CVDs) was 29.4%. The prevalence rate increased with age, from 22% in the 45-54 age group to 38% in the 70+ age group, showing that the senior population is at high risk of having CVDs. Such prevalence of various cardiovascular conditions is expected to drive the demand for drug-eluting balloons as they are used to treat various cardiovascular conditions, thereby helping in the recovery of affected patients.
However, the high cost of development and commercialization of drug-eluting balloons, coupled with stringent regulatory procedures, are hampering the market growth.
Drug Eluting Balloon Market Trends
Peripheral Drug-eluting Balloons are Expected to Grow at a Healthy Rate Over the Forecast Period
Drug-eluting balloons play an important role in the treatment of peripheral artery diseases. The growing prevalence of peripheral artery diseases, coupled with the increasing geriatric population, is expected to boost segment growth.
According to the American Heart Association 2021 report, peripheral artery disease (PAD) affects more than 200 million people worldwide and is associated with high mortality and morbidity. With the aging global population, PAD may likely become increasingly common. Statistics show that PADs are increasing at a faster pace, which is ultimately driving the segment for peripheral drug-eluting balloons. Another scientific study published by the American Heart Association in August 2021 stated that lower extremity PAD affects more than 230 million people worldwide and is linked to an elevated risk of several unfavorable clinical outcomes (including cardiovascular diseases like coronary heart disease and stroke and limb outcomes, like amputee status). The increased incidence of PAD is expected to boost the use of peripheral drug-eluting balloons over the forecast period.
The segment for peripheral drug-eluting balloons is expected to have a significant share owing to the increased usage of drug-eluting balloons in the treatment of peripheral artery diseases and growing R&D in expanding the indications, and new product launches in the peripheral artery segment.
The anticipated product launches, coupled with the development of innovative coating and balloon technologies, are expected to boost the segment's growth over the forecast period.
North America is Expected to Have Significant Market Share Over the Forecast Period
The major factors attributing to the growth are a sedentary lifestyle lacking physical activity, lack of proper diet, anxiety, and stress resulting in chronic diseases, such as diabetes and obesity, leading to an increase in the prevalence of multiple cardiovascular diseases like coronary artery disease, strokes, and atrial fibrillation.
The data updated by Cedars-Sinai in January 2022 showed that coronary artery bypass graft surgery (CABG), also known as coronary artery bypass, or bypass surgery, is the most common type of heart surgery. More than 300,000 people have successful bypass surgeries in the United States each year. Such a burden of various cardiovascular disease-related surgical procedures is expected to drive the demand for drug-eluting balloons and provide lucrative opportunities for the growth of the market in this region.
In addition, the Centers for Disease Control and Prevention (CDC) data updated in July 2022 showed that coronary heart disease is the most common type of heart disease, and approximately 20.1 million adults of age 20 and older had the disease in the United States. Per the CDC data, every 40 seconds, someone suffers from a heart attack, and nearly 805,000 people in the United States have a heart attack every year. Thus, the high burden of cardiovascular diseases demands the availability of drug-eluting balloons.
The presence of a large pool of people with heart diseases and growing healthcare spending, especially in emerging countries of North America, are expected to boost the market growth.
Drug Eluting Balloon Industry Overview
The drug-eluting balloon market is moderately consolidated and competitive. Companies are focusing on innovating balloon technologies and expanding product indications to increase their market share. The key market players operating in the market include Medtronic PLC, Boston Scientific Corporation, Becton, Dickson and Company, Terumo Corporation, and Koninklijke Philips NV, among others.
Drug Eluting Balloon Market Leaders
-
Boston Scientific Corporation
-
Becton, Dickson and Company
-
Terumo Corporation
-
Medtronic PLC
-
Koninklijke Philips NV
- *Disclaimer: Major Players sorted in no particular order
Drug Eluting Balloon Market News
- September 2022: Advanced NanoTherapies received the US FDA approval for its SirPlux Duo Drug Coated Ballon for coronary artery disease in vessels less than 3.0 mm.
- May 2022: MedAlliance's SELUTION SLR drug-eluting Ballon received FDA investigational device exemption approval. The SELUTION SLR provides a controlled, sustained drug release for below-the-knee indications in peripheral artery disease.
Drug Eluting Balloon Industry Segmentation
Drug-eluting balloons are semi-compliant angioplasty balloons that are used to elute the drug in the targeted vessel. Drug-eluting balloons may be coated or non-coated.
The drug-eluting balloon market is segmented by product (coronary drug-eluting balloon, peripheral drug-eluting balloon, and other products (renal/urology)), technology (FreePac, TransPac, EnduraCoat, and other technologies), end users (hospitals, ambulatory surgical centers, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also provides the estimated market sizes and trends for 17 different countries. The report offers the value (in USD million) for the above segments.
| By Product | Coronary Drug-eluting Balloon | ||
| Peripheral Drug-eluting Balloon | |||
| Other Products (Renal/Urology) | |||
| By Technology | FreePac | ||
| TransPac | |||
| EnduraCoat | |||
| Other Technologies | |||
| By End User | Hospitals | ||
| Ambulatory Surgical Centers | |||
| Other End Users | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| Coronary Drug-eluting Balloon |
| Peripheral Drug-eluting Balloon |
| Other Products (Renal/Urology) |
| FreePac |
| TransPac |
| EnduraCoat |
| Other Technologies |
| Hospitals |
| Ambulatory Surgical Centers |
| Other End Users |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Drug Eluting Balloon Market Research Faqs
What is the current Drug Eluting Balloon Market size?
The Drug Eluting Balloon Market is projected to register a CAGR of 18% during the forecast period (2025-2030)
Who are the key players in Drug Eluting Balloon Market?
Boston Scientific Corporation, Becton, Dickson and Company, Terumo Corporation, Medtronic PLC and Koninklijke Philips NV are the major companies operating in the Drug Eluting Balloon Market.
Which is the fastest growing region in Drug Eluting Balloon Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Drug Eluting Balloon Market?
In 2025, the North America accounts for the largest market share in Drug Eluting Balloon Market.
What years does this Drug Eluting Balloon Market cover?
The report covers the Drug Eluting Balloon Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Drug Eluting Balloon Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Drug Eluting Balloon Industry Report
Statistics for the 2025 Drug Eluting Balloon market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Drug Eluting Balloon analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
